CPC-152 Use of Omalizumab in Chronic Cold Urticaria: A Case Report

Abstract

Background Omalizumab is a recombinant humanised monoclonal antibody which prevents the binding of IgE to the high-affinity receptor
type I (FcεRI). A complicated series of reactions results in a reduction of free IgE responsible for the allergic inflammatory
cascade. Omalizumab is indicated as add-on therapy to improve asthma control in adults and adolescents (from 12 years). In
addition, several studies show that omalizumab is effective in the treatment of chronic urticaria.

Purpose We report the case of a patient with chronic cold urticaria resistant to conventional treatments.

Materials and Methods The patient was a 67-year-old man, who had suffered from chronic urticaria for over 30 years. The disease was disclosed
by pressure urticaria, which had been neglected for a long time. It then turned into a cold urticaria in the 90s. The latter
showed itself in 2002 as the patient experienced an anaphylactic shock in a bath at 24°C.

Results Several lines of treatment, all unsuccessful, were tested on the patient: high-dose H1 antihistamine, montelukast, methotrexate,
anakinra. In view of this therapeutic impasse, omalizumab appeared as an alternative: doses of 375 mg were administered to
him every 15 days as a start. In total, 12 treatments were performed in dermatology outpatients. No side effects were encountered
except for an episode of nausea. The results were: a decrease in consumption of H1 antihistamine, ice test negative and significant
clinical improvement of his urticaria.

Conclusions In view of the results obtained for this patient, omalizumab appears to be an alternative for treating chronic urticaria in
treatment failure. Indeed, it is well tolerated, the risk-benefit ratio is positive, the only problem is the cost incurred
for such care.